Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism Hsp47 inhibitors(Serpin H1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Innovo Therapeutics Co. Ltd.Startup |
Active Organization Innovo Therapeutics Co. Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cicatrix | Phase 2 | - | Innovo Therapeutics Co. Ltd.Startup | 02 Nov 2022 |
Phase 2 | 77 | gasdxajkkc(avfzahxsks) = A trend of lower scores was observed in each treatment group compared to the placebo. Additionally, the within-group score change from baseline to 12 weeks was statistically significantly reduced in the high-dose (2%) treatment group. xneutqzbim (whfckbcsuv ) View more | Positive | 21 Aug 2024 | |||
Placebo |